Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PREP | P48147 | 4/20 | 0.39 |
| ▸ | CA12 | O43570 | 2/20 | 0.36 |
| ▸ | CA1 | P00915 | 2/20 | 0.36 |
| ▸ | CA9 | Q16790 | 2/20 | 0.36 |
| ▸ | AKR1C3 | P42330 | 2/20 | 0.36 |
| ▸ | AKR1C2 | P52895 | 2/20 | 0.36 |
| ▸ | FFAR1 | O14842 | 6/20 | 0.36 |
| ▸ | PPARA | Q07869 | 4/20 | 0.35 |
| ▸ | PPARG | P37231 | 2/20 | 0.34 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1508333 | 0.83 | PREP (0.37) | PREPCA12CA1CA9AKR1C3 | |
| SCHEMBL10317583 | 0.81 | FFAR1 (0.55) | FFAR1PPARG | |
| SCHEMBL29142835 | 0.78 | PREP (0.42) | PREPCA12CA1CA9AKR1C3 | |
| SCHEMBL10469262 | 0.78 | PTGS2 (0.46) | PREPCA12CA1CA9AKR1C3 | |
| SCHEMBL24328885 | 0.77 | HPGD (0.51) | CA1AKR1C3AKR1C2AKR1C1HPGD | |
| SCHEMBL1508330 | 0.76 | FFAR1 (0.42) | PREPFFAR1PPARG | |
| SCHEMBL1508290 | 0.76 | FFAR1 (0.45) | FFAR1PPARG | |
| SCHEMBL4942414 | 0.76 | CYP1A2 (0.46) | PPARAPPARG | |
| SCHEMBL14762693 | 0.75 | PPARG (0.47) | FFAR1PPARAPPARG | |
| SCHEMBL14762470 | 0.75 | ALDH1A1 (0.41) | PREPCA12CA1CA9FFAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9096531-B2 | Fused imidazole derivative | TOA EIYO LTD. (JP) | 2015-08-04 | — | — | US | disclosed |
| EP-2578573-A1 | FUSED IMIDAZOLE DERIVATIVE | TOA Eiyo Ltd. (JP) | 2013-04-10 | — | — | EP | disclosed |
| US-20130065896-A1 | FUSED IMIDAZOLE DERIVATIVE | TOA EIYO LTD. (JP) | 2013-03-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130065896-A1 | FUSED IMIDAZOLE DERIVATIVE | CACNA1E, CACNA1G, CACNA1A | PREP 4702/4885CA12 3403/4885CA1 328/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.